PAZEO® Solution SAFETY PROFILE

mom-baby The safety and effectiveness of PAZEO® Solution have been established in patients aged 2 years and older1

Warnings and Precautions

  • As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle to prevent contaminating the tip and solution. Keep bottle tightly closed when not in use
  • Patients should not wear a contact lens if their eye is red. PAZEO® Solution should not be used to treat contact lens-related irritation. The preservative in PAZEO® Solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least five minutes after instilling PAZEO® Solution before they insert their contact lenses

Adverse Reactions

A total of 499 subjects participated in the phase III clinical safety trial involving treatment for 6 weeks, of which 330 were treated with PAZEO® Solution.1

The most commonly reported adverse reactions, occurring in 2% to 5% of patients treated with either PAZEO® Solution or vehicle:

  • Blurred vision, dry eye, superficial punctate keratitis, dysgeusia, and abnormal sensation in eye1
Learn how to help eligible patients save with the PAZEO® Solution Co-Pay Savings Card*
See how many of your patients could be suffering from ocular allergy itch

INDICATION AND DOSING

PAZEO® Solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis. The recommended dosage is to instill one drop in each affected eye once a day. 

IMPORTANT SAFETY INFORMATION

As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle to prevent contaminating the tip and solution. Keep bottle tightly closed when not in use. 

Patients should not wear a contact lens if their eye is red. PAZEO® Solution should not be used to treat contact lens-related irritation. The preservative in PAZEO®Solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least five minutes after instilling PAZEO® Solution before they insert their contact lenses. 

The most commonly reported adverse reactions in a clinical study occurred in 2%-5% of patients treated with either PAZEO®Solution or vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia, and abnormal sensation in eye. 

For additional information on PAZEO® Solution, please click here to view the full Prescribing Information.

*Terms and Conditions:

Limitations apply. For commercially insured patients. Up to a $125 cap per bottle. Patient will be responsible for any co-pay once limit per bottle is reached. This offer is not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients. Novartis reserves the right to rescind, revoke, or amend this program without notice. Offer expires 12/31/2017.

Reference: 1. PAZEO® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2016.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION & DOSING

PAZEO®Solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis. The recommended dosage is to instill one drop in each affected eye once a day. 

IMPORTANT SAFETY INFORMATION

As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle to prevent contaminating the tip and solution. Keep bottle tightly closed when not in use. 

Patients should not wear a contact lens if their eye is red. PAZEO® Solution should not be used to treat contact lens-related irritation. The preservative in PAZEO®Solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least five minutes after instilling PAZEO® Solution before they insert their contact lenses. 

The most commonly reported adverse reactions in a clinical study occurred in 2%-5% of patients treated with either PAZEO®Solution or vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia, and abnormal sensation in eye. 

For additional information on PAZEO® Solution, please click here to view the full Prescribing Information.

*Terms and Conditions:

Limitations apply. For commercially insured patients. Up to a $125 cap per bottle. Patient will be responsible for any co-pay once limit per bottle is reached. This offer is not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients. Novartis reserves the right to rescind, revoke, or amend this program without notice. Offer expires 12/31/2017.

Reference: 1. PAZEO® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2016.

Olopatadine is licensed from Kyowa Hakko Kirin Co., Ltd. Japan

PAZEO is a registered trademark of Novartis AG.

Additional Novartis Information

Medical Information

6/17 T-PAL-1342459

Use of website is governed by the Terms of Use and Privacy Policy.

© 2017 Novartis Pharmaceuticals Corporation. All rights reserved.